Article ; Online: Decrease in ultrasound Brain Tissue Pulsations as a potential surrogate marker of response to antidepressant.
Journal of psychiatric research
2022 Volume 146, Page(s) 186–191
Abstract: Previous cross-sectional studies found excessive Brain Tissue Pulsations (BTP) in mid-life depression, which could constitute a mechanism of brain damage in depression. However, it remains unclear whether successful antidepressant therapy restores BTP ... ...
Abstract | Previous cross-sectional studies found excessive Brain Tissue Pulsations (BTP) in mid-life depression, which could constitute a mechanism of brain damage in depression. However, it remains unclear whether successful antidepressant therapy restores BTP amplitudes. In this prospective study, we investigated longitudinal changes in BTP in patients with a major depressive episode (MDE), among responders and non-responders to escitalopram. Fifty-two individuals with a MDE, free of antidepressants at baseline, were included in an 8-week open-labeled escitalopram trial. Ultrasound Tissue Pulsatility Imaging (TPI) was applied to measure resting BTP and BTP reactivity in an orthostatic challenge, at baseline and at week 8. TPI data were available for 48 participants divided into responders (n = 28, 58.3%) and non-responders (n = 20, 41.7%) according to change in the MADRS score. MaxBTP significantly decreased between baseline and week 8, only in responders. In addition, changes in MaxBTP during the orthostatic challenge were no longer significant at week 8 but only in responders. Because excessive BTP constitutes a potential mechanism for brain damage, our results suggest that a successful pharmacotherapy could benefit patients to lower the risk of brain damage in individuals with depression, a population exposed to stroke, small arteries disease and brain atrophy. TPI could provide a surrogate biomarker to monitor antidepressant response and brain health in depression in clinical routine. |
---|---|
MeSH term(s) | Antidepressive Agents/therapeutic use ; Biomarkers ; Brain/diagnostic imaging ; Citalopram/therapeutic use ; Depressive Disorder, Major/diagnostic imaging ; Depressive Disorder, Major/drug therapy ; Humans ; Prospective Studies ; Treatment Outcome |
Chemical Substances | Antidepressive Agents ; Biomarkers ; Citalopram (0DHU5B8D6V) |
Language | English |
Publishing date | 2022-01-03 |
Publishing country | England |
Document type | Clinical Trial ; Journal Article ; Research Support, Non-U.S. Gov't |
ZDB-ID | 3148-3 |
ISSN | 1879-1379 ; 0022-3956 |
ISSN (online) | 1879-1379 |
ISSN | 0022-3956 |
DOI | 10.1016/j.jpsychires.2021.12.056 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Ui I Zs.243: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.